1. Home
  2. XBIT vs NEN Comparison

XBIT vs NEN Comparison

Compare XBIT & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.43

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Logo New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

NEN

New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

HOLD

Current Price

$60.90

Market Cap

209.2M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
XBIT
NEN
Founded
2005
1977
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
74.4M
209.2M
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
XBIT
NEN
Price
$2.43
$60.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
20.1K
831.0
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
2.71%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$89,196,544.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$19.68
Revenue Growth
N/A
10.76
52 Week Low
$2.09
$56.00
52 Week High
$3.61
$75.00

Technical Indicators

Market Signals
Indicator
XBIT
NEN
Relative Strength Index (RSI) 48.22 54.51
Support Level $2.35 $57.00
Resistance Level $2.49 $66.30
Average True Range (ATR) 0.06 0.66
MACD -0.01 0.24
Stochastic Oscillator 42.86 100.00

Price Performance

Historical Comparison
XBIT
NEN

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

Share on Social Networks: